Geneerinen Daclatasvir - , Daklinza, Natdac, Hepcinat, Myhep, Sofovir

Geneerinen Daklinza on viruslääke, joka estää hepatiitti C –virusta (HCV) moninkertaistumasta kehossa. Daclatasviriä käytetään hoitamaan 3. genotyypin kroonista C hepatiittia aikuisilla, joilla ei ole kirroosia. Tätä lääkettä annetaan yhdessä sofosbuvir­nimisen lääkkeen kanssa.

Natdac® is an inhibitor of the viral (hepatitis C virus) protein NS5A, which is used in the replication of hepatitis C virus within the liver cells (hepatocytes) and, thus, prevents the virus from entering infected hepatocytes into the blood. Thanks to this action, it is possible to prevent the spread of the virus in the body. Natdac® (daсlatasvir) is a highly specific direct action agent against hepatitis C virus (HCV) and has no pronounced activity against other RNA and DNA containing viruses, including human immunodeficiency virus (HIV). Natdac®, as an inhibitor of the nonstructural protein 5A (NS5A), a multifunctional protein required for HCV replication, suppresses two stages of the life cycle of the virus-viral RNA replication and virion assembly.

Hepcinat - sisaltaa Sofosbuvir 400mg, uusin laake kehittanyt Intialainen yritys Natco Pharma avulla high-tech-laitteet, kanssa kaikki tarvittavat standardit ja vaatimukset. Laake on kaytetty hoitoon krooninen hepatiitti C. Hoidon sofosbuvir kaytetaan monimutkaisia muiden viruslaakkeiden aikana ilman interferoni hoito' lahes kaikki johtava klinikoilla ympari maailmaa, koska tama laake, joka on tehty paljon kliinisia ja laboratoriotutkimuksia, osoitti hyvia tuloksia. Tehokkuutta uuden laakkeen eri genotyyppien virus on 92-96%.

Myhep® - sofosbuvir 400mg - is used to treat chronic hepatitis C as a component of a combined antiviral therapy regimen in adult patients in combination with other medications. Myhep® is a direct-acting antiviral that inhibits the RNA-dependent NS5B polymerase of the hepatitis C virus, which is essential for viral replication. Myhep® is a drug manufactured by Mylan Pharmaceuticals, based in India. All the products of this company are produced on modern equipment of a large plant built according to all norms and regulations of the World Health Organization.

Sofovir® is an Indian registered licensed analog of Sovaldi (Sofosbuvir). It is an inhibitor of the NS5B polymerase of hepatitis C virus (HCV) that contains 400mg of the active substance Sofosbuvir. It is used to treat chronic hepatitis C as a component of a combined antiviral therapy regimen in adults. Sofovir® can be used by patients who have not been treated before or who have had unsuccessful experience in the treatment of hepatitis C. Good efficacy has been shown with concomitant serious liver pathologies like cirrhosis and HIV infection.